Search results for " DAP."
showing 10 items of 22 documents
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-…
2017
Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…
Daptomycin non-susceptible, vancomycin intermediate methicillin-resistant Staphylococcus aureus ST398 from a chronic leg ulcer, Italy
2010
To the Editor,Human infections caused by methicillin-resistant Staphylococcus aureus (MRSA) sequence type 398 (ST398) have been emerging in recent y in Europe [1–3]. Most studies have shown a stron...
Systemic lupus erythematosus and bullous pemphigoid with dramatic response to dapsone
2017
Patient: Female, 11 Final Diagnosis: Bullous pemphigoid in systemic lupus erythematosus Symptoms: Bullous lupus • photosensitive rash • synovitis Medication:— Clinical Procedure: Pharmacological treatment Specialty: Rheumatology Objective: Unusual clinical course Background: Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs. Case Report: We describe the clinical case of an 11-year-old girl with SLE. She showed bullous skin les…
Ripensare l’alleanza terapeutica attraverso lo studio del processo terapeutico nella cura del panico. Due terapie ad orientamento psicodinamico.
2009
Il Disturbo da Attacchi di Panico (DAP) è, sul piano clinico, una sindrome acuta e cronica, ad alta incidenza epidemiologica, che costituisce oggi, insieme alla fobia sociale e alla depressione, una delle tre maggiori cause d’invalidità della popolazione e, conseguentemente, una delle maggiori fonti di costi sociali, medici e psichiatrici (DSM-IV-TR, 2000). In questo articolo, assumendo il concetto di relazione come elemento caratterizzante il trattamento terapeutico, si cerca di connettere la manifestazione fenomenologica del panico alle modalità relazionali del soggetto e al loro significato. Si cerca di adottare questo “sguardo” anche in una prospettiva di ricerca, attraverso la “lente” …
AUTOPHAGY AND APOPTOSIS MODULATION BY AQUEOUS EXTRACTS FROM LEAVES AND RHIZOMES OF Posidonia oceanica ON HEPG2 HEPATOCARCINOMA CELLS
2023
Alleanza terapeutica, Meccanismi di difesa ed Esiti nel trattamento del DAP. Analisi di una interruzione di trattamento. Uno studio single-case
2008
Sexual abuse and maltratment on child: protocols, cooperation strategies, daphne II - V.eR.S.O. (Violenza e reti sanitarie operative) Project- our ex…
2008
Recensione di: "Longus, Daphnis and Chloe", edited by E. Bowie, Cambridge 2019
2022
Review to the volume "Longus, Daphnis and Chloe"
Interessos: Assignació de polítiques dels Estats jurídiques entre universalisme i regionalisme
2012
Xerrada sobre interessos deslocalitzats donada en el congrés sobre lleis regionals i internacionals realitzat a València del 13 al 15 de setembre.
SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class
2019
Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…